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Abstract 
Background: Gaps persist in HIV testing for children who were not tested in prevention of mother-to-
child HIV transmission programs. Oral mucosal transudate rapid HIV tests (OMT) have been shown to 
be highly sensitive in adults but their performance has not been established in children.  
 
Methods: ART-naïve children aged 18 months to 18 years in Kenya and Zimbabwe were tested for 
HIV using rapid OraQuick ADVANCE Rapid HIV-1/2 Antibody test on oral fluids (OMT) and blood-
based rapid diagnostic testing (BBT). BBT followed Kenyan and Zimbabwean national algorithms. 
Sensitivity and specificity were calculated using the national algorithms as the reference standard. 
 
Results: A total of 1,776 children were enrolled; median age was 7.3 years (IQR: 4.7, 11.6). Among 71 
children positive by BBT, 71 were positive by OMT (sensitivity: 100% [97.5%CI: 94.9-100%]). Among 
the 1,705 children negative by BBT, 1,703 were negative by OMT (specificity: 99.9% [95%CI: 99.6-
100.0%]). Due to discrepant BBT and OMT results, 2 children who initially tested BBT negative and 
AC
CE
PT
ED
 Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. 9
 4
OMT positive were subsequently confirmed positive within 1 week by further tests. Excluding these 2 
children, the sensitivity and specificity of OMT compared to BBT were each 100% (97.5%CI: 94.9-
100% and 99.8-100%, respectively).  
 
Conclusions: Compared to national algorithms, OMT did not miss any HIV-positive children. These 
data suggest that OMTs are valid in this age range. Future research should explore the acceptability and 
uptake of OMT by caregivers and health workers to increase pediatric HIV testing coverage. 
 
Key Words: HIV, children, pediatric, oral HIV testing, diagnostic, saliva HIV testing 
 
Introduction 
The HIV pandemic has heavily affected children with over 1.8 million children (<15 years) living with 
HIV and 180,000 newly infected in 2017 1. Prompt diagnosis and initiation on antiretroviral therapy 
(ART) is associated with decreased morbidity and mortality 2,3 and improved developmental outcomes 
4,5; however, gaps remain in diagnosis, particularly among older children and adolescents 6. 
 
World Health Organization (WHO) recommendations endorse rapid antibody-based HIV tests for 
diagnosis of individuals >18 months 7. Blood-based HIV tests (BBT) are used globally. Additionally 
oral mucosal transudate rapid HIV tests (OMT) allow for  sample collection that is less invasive, are 
more acceptable to clients, poses fewer risks to healthcare workers (HCW), and may increase testing 
uptake 8-10. 
 
The Food and Drug Administration (FDA) approved the OraQuick OMT in 2004 for testing by health 
providers for individuals >12 years 11. In 2016 the OraQuick HIV Self-Test received WHO 
prequalification  and it is now recommended by WHO as a screening test for HIV 12. OMT has high 
sensitivity and specificity in detecting HIV antibodies in adults and older adolescents 7,10. A meta-
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analysis comparing OMT with BBT in adults reported a pooled sensitivity of 98.0% and specificity of 
99.7% for OMT 10. OMT has not been validated in children. 
 
We evaluated the diagnostic performance of OMT compared to routine BBT in children and adolescents 
aged 18 months to 18 years in Kenya and Zimbabwe. 
 
METHODS 
 
Setting & Participants: 
This analysis includes pooled data from two studies in Kenya and Zimbabwe that include parallel point 
of care diagnostic OMT and BBT to assess sensitivity and specificity of OMT among children and 
adolescents. Data was combined to increase precision of sensitivity and specificity estimates, as the 
number of newly diagnosed HIV-positive children in both settings has reduced with the scale-up of 
pediatric HIV prevention and treatment programmes. 
 
Zimbabwe: This analysis was nested within the “Bridging the Gap in HIV Testing and Care for 
Children in Zimbabwe” (B-GAP Project) whose aim is to evaluate index-linked testing for pediatric 
case detection. Study participants were children and adolescents of unknown HIV status, aged 2-18 
years, attending any health services in the participating hospitals and primary healthcare clinics.  
Kenya: The “Saliva Testing and Video Information to Expand Uptake of Pediatric HIV Testing” 
(STEP-UP) study enrolled children aged 18 months to 12 years. Two recruitment streams were used. 
First, children of HIV-positive adults attending HIV clinics who were tested for HIV within a 
randomized controlled trial of financial incentives for index case testing (FIT trial; NCT03049917 13) 
were recruited after determining HIV status using BBT within the trial. Second, children from 
outpatient clinics were recruited after HIV testing using BBT within routine testing; here children who 
tested BBT positive were oversampled. 
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Procedures:  
Zimbabwe: Testing followed the national algorithm 14: first, BBT by Determine (Alere DetermineTM 
HIV-1/2 Ag/Ab Combo – Abbott, Illinois, USA) (4th generation), followed by First Response (First 
Response HIV-1-2, Premier Medical Corporation Ltd., Kachigam, India) (3rd generation) if Determine 
was reactive. In the case of two reactive BBTs, the same two BBTs were performed by a different 
provider to confirm a positive diagnosis. In the case of discordant BBTs, both tests were repeated. If 
discordance persisted, a third test, CHEMBIO was performed (CHEMBIO HIV 1/2 STAT-PAK Assay, 
CHEMBIO Diagnostic Systems, Inc., New York, USA). If this third test was positive, the result was 
reported as inconclusive and a retest conducted in 14 days. OMT was conducted by clinic staff blinded 
to BBT results.  
Kenya: The national algorithm mirrored that in Zimbabwe with the following exceptions: the Determine 
HIV test was 3rd instead of 4th generation and DNA PCR from dry blood spot specimens was the third 
test and was considered conclusive 14-16. Additionally, BBT was performed by non-research staff. 
Research staff performed OMT and were not blinded to BBT results. 
 
The reference standard used for our study was the HIV status as per the national algorithim of each 
country.  
 
OMT: In Zimbabwe and Kenya, OMT sample collection and processing was performed bedside by 
qualified HIV testing lay providers who are typically lower than nurse level providers and are 
responsible for HIV testing in both countries. The qualification for these providers is a standard national 
training for HIV services conducted over two weeks. Testing was conducted according to manufacturer 
details (OraQuick ADVANCE Rapid HIV-1/2 Antibody Test - OraSure Technologies Inc., Bethlehem, 
PA) whereby the research staff collected an oral fluid sample from the participants by running the test 
device between the lips and outer gums of the client once on top and once on bottom and then place the 
test device pad directly into the reaction fluid immediately after collection17. OMT results were read 
once between 20 and 40 minutes in Zimbabwe, and twice in Kenya at both 20 and 40 minutes to assess 
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test performance at the lower and upper recommended times. OMT results were not shared with 
caregivers, as the test was undergoing validation. 
 
Statistical analysis 
Data were analyzed using STATA14 (StataCorp, College Station, TX, USA). Sensitivity was calculated 
by dividing the number of OMT positive children by the number of BBT positive children. Specificity 
was calculated by dividing the number of OMT negative children by the number of BBT negative 
children. Positive predictive value (PPV) and negative predictive value (NPV) were calculated in the 
Zimbabwean cohort by dividing the number with both positive OMT and BBT by all the positive OMT 
tests (PPV) and by dividing the number with both negative OMT and BBT results by the total negative 
by OMT (NPV). PPV and NPV were not calculated in the Kenyan cohort because positive children 
were oversampled. Ninety-five percent (95%) or 97.5% (when the estimate was 100%) confidence 
intervals (CI) were calculated using a binomial distribution. Stability of the test results using results 
interpretation pictures from the manufacturer was described in Kenya.  
 
Ethics  
Adolescents >=16 gave independent written informed consent without parental/guardian consent. 
Parents/guardians of children aged 18 months - 15 years provided written consent; adolescents 13-15 
years signed a paragraph within the parental consent form to give their assent while children 7-12 
signed a separate assent document, which was optional in Kenya. B-GAP received approval from the 
Biomedical Research and Training Institute, the Medical Research Council of Zimbabwe and 
institutional review boards at Duke University and the London School of Hygiene and Tropical 
Medicine. The Kenya study received approval from the Kenyatta National Hospital Ethics and Research 
Committee and the University of Washington Institutional Review Board. 
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RESULTS 
Demographics  
Overall, 1,776 children were enrolled; 1,570 (88%) from Zimbabwe and 206 (12%) from Kenya. The 
median age was 7.3 years (interquartile range [IQR]: 4.7, 11.6); 2 (0.1%) were 18 months -2 years; 512 
(29%) were >2-5 years; 845 (48%) were >5-12 years; 417 (23%) were >12-18 years. Overall, 918 
(52%) were female. Among Kenyan children, 169 (82%) were identified via index case testing (ICT) 
and 37 (18%) in outpatient clinics and inpatient wards.  
 
OMT sensitivity and specificity  
Among 71 children positive by BBT, 71/71 (sensitivity: 100% [97.5% CI: 94.9-100%]) were positive 
by OMT. Among 1,705 children negative by BBT, 1,703/1,705 (specificity: 99.9% [95% CI: 99.6-
100.0%]) were negative by OMT. In the 1,570 Zimbabwean participants, the PPV was 93.3% (95%CI: 
77.9%-99.2%) and the NPV was 100.0% (97.5%CI: 99.8% -100.0%). 
 
In Zimbabwe, two children who initially tested BBT negative and OMT positive were retested within 1 
week to confirm HIV status because of suggestive clinical presentation and history; both were 
confirmed positive. A 9 year old was confirmed positive by ELISA. A 2 year old was confirmed 
positive by First Response and CHEMBIO. Excluding these 2 children, the sensitivity and specificity of 
OMT compared to BBT were each 100% (97.5%CI: 94.9-100% and 99.8-100%, respectively) (Table 
2). 
 
Stability of visual results (Kenya) 
Among 43 children with positive OMT at 20 minutes, 43 (100%) had positive OMT at 40 minutes. 
Among the 163 children with negative OMT at 20 minutes, 163 (100%) had a negative OMT at 40 
minutes. Using results interpretation pictures from the manufacturer, among 43 positive OMT results, 
26 (60%) and 29 (67%) were strongly positive at 20 and 40 minutes, respectively. Three reads that were 
weakly positive at 20 minutes were strongly positive by 40 minutes.  
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DISCUSSION 
In this cross sectional study of children ages 18 months to 18 years, we found that OMT had excellent 
sensitivity and specificity. When compared to the Kenyan and Zimbabwean national algorithms, OMT 
did not miss any positive children. These data suggests that OMT is valid for HIV diagnosis in this age 
range. 
 
As with other antibody tests, OMT is inappropriate as a diagnostic test for children under 18 months 
due to the presence of maternal antibodies 18. In adults, antibody-based tests have limitations due to a 
long window period, which may lead to failure in detecting recent HIV infection 19. However, this is 
less of a concern among older children and younger adolescents who, if infected, are likely to have 
long-standing HIV acquired perinatally.  
 
Our results provide evidence for wider use of OMT for pediatric testing. Current testing approaches to 
identify children include index-linked testing, provider-initiated testing and counseling (PITC), targeted 
testing in health facilities, and community-based testing 6,7,20-26. Outpatient PITC can identify children 
earlier in disease progression27; however, achieving high coverage is challenging 21 due to high client 
volume and workload for limited numbers of HCWs 28. In resource-limited settings, scaling up testing 
will require simultaneously increasing coverage and minimizing costly components of testing, including 
HCW time 29,30. The ease and safety of OMT presents a potential opportunity for task-shifting from 
HCWs to lay providers as was done in this study or to caregivers to overcome human resource 
constraints. It is also important to note that the time to perform and throughout for OMT is also similar 
to that required for BBT. Future research is needed to explore the acceptability and feasibility of OMT 
by caregivers, and HCW in facility and community settings. 
 
A 2012 systematic review comparing OMT with whole blood specimens reported a pooled sensitivity of 
98.0% and specificity of 99.7% for OMT10.  Despite this, the concentration of antibodies in oral fluid is 
lower than in blood and typically wanes during HIV treatment 31,32. Prior studies in Zimbabwe have 
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confirmed that OMT has suboptimal sensitivity in ART-experienced children 29,33. WHO has issued 
warnings, advocating that rapid diagnostic tests not be used among ART-experienced adults; similar 
warnings appear warranted in children. Therefore, it is critical to avoid use of OMT by ART-
experienced patients, either to confirm being “cured” of HIV or when reinitiating HIV care 34. Our 
study included an entirely ART-naïve pediatric population and observed no false negative results. In 
two cases, children were negative by BBT and positive by OMT and were confirmed HIV-positive upon 
repeat testing. This suggests slightly better detection by OMT than BBT in our study; it is unclear why 
we observed this counterintuitive finding.  
 
Our study’s strengths include a large sample of ART-naïve, HIV-positive children to inform precise 
estimates of sensitivity. In addition data from Kenya and Zimbabwe provided similar results. OMT 
results were compared to routine, field-based BBT according to national algorithms, which provides an 
apt comparison with standard of care tests and provides useful public health information. Limitations 
include that OMT result interpretation was not blinded in Kenya, which may have influenced result 
interpretation. National algorithms between the two countries differed slightly, so the “reference 
standard” was not the same in both countries. However, in both cases, the algorithms are those used for 
national guidelines. Consequently our findings demonstrate the performance of OMT against the 
standard of care and are therefore generalizable in these settings. While the BBT in this study were not 
ELISA or PCR, OMT has previously been compared with these more sensitive lab-based tests to inform 
FDA approval and WHO endorsement for adults 11,31. An additional limitation is that in our study we 
did not have any inconclusive test results. Procedures on how to report and manage inconclusive test 
results must be put in place.  
 
CONCLUSION 
OMT is highly sensitive and specific in children and adolescents. This is consistent with findings from 
studies in adult populations. Policymakers and regulators should consider expanding the age in which 
OMT may be used to include children over 18 months. 
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TABLES 
Table 1: Sociodemographic characteristics 
Table 2: Performance of OMT vs BBT for HIV diagnosis 
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TABLES & FIGURES 
 Table 1: Sociodemographic characteristics 
 
 
 
 
*BBT: Blood based 
test  
#IQR: interquartile 
range  
 
 
 
 
 
 
 
 
 
  
 
All  
N=1776 
BBT* HIV-
positive n=71 
BBT HIV-
negative 
n=1705 
Child characteristics n (%) or 
median (IQR#) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
Age group     18mths -
2 years     2 (0.1) 1 (1)     1 (0.1) 
>2-5 years 512 (29) 21 (30) 491 (29) 
>5-12 years 845 (48) 34 (48) 811 (48) 
>12-18 years 417 (23) 15 (21) 402 (24) 
Female  918 (52) 46 (65)  872 (51) 
Recruitment country 
   
    Zimbabwe 1570 (88) 28 (39) 1542 (90) 
    Kenya 206 (12) 43 (61)   163 (10) 
    Index case testing 169 (82)   7 (16) 162 (99) 
    Inpatient/outpatient   37 (18)  36 (84)   1 (1) 
 
   
PMTCT History 
(Kenya) 
All  
n=189 
BBT* HIV-
positive n=43 
BBT HIV-
negative  
n=146 
Tested positive in 
pregnancy  8 (4)            5 (12) 3 (2) 
Any maternal ARVs  4 (50)            2 (40) 2 (67) 
Any infant prophylaxis  4 (50)            2 (40) 2 (67) 
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Table 2: Performance of OMT vs BBT for HIV diagnosis overall ans stratified by site  
Panel A: Overall results  
  
BBT 
  
Positive Negative N 
OMT 
Positive 71 2* 73 
Negative 0 1703 1703 
Total 71 1705 1776 
 
*subsequently confirmed as HIV-positive using additional tests 
within 1 week of initial testing 
 
Sensitivity 100%  (97.5% CI 94.9-100)  
 
Specificity (including 2 discrepant) 99.9% (95% CI 99.6-100) 
 
Specificity (excluding 2 discrepant) 100% (97.5% CI 99.8-100) 
 
Panel B: Zimbabwe  
 
  
BBT 
  
Positive Negative N 
OMT 
Positive 28 2* 30 
Negative 0 1540 1540 
Total 28 1542 1570 
 
*subsequently confirmed as HIV-positive using additional tests 
within 1 week of initial testing 
 
Sensitivity 100%  (97.5% CI 87.7-100)  
 
Specificity (including 2 discrepant) 99.9% (95% CI 99.5-100) 
 
Specificity (excluding 2 discrepant) 100% (97.5% CI 99.8-100) 
 
Panel C: Kenya  
  
BBT 
  
Positive Negative N 
OMT 
Positive 43 0 43 
Negative 0 163 163 
Total 43 163 206 
  
 
Sensitivity 100%  (97.5% CI 91.8-100)  
 
Specificity (excluding 2 discrepant) 100% (97.5% CI 97.8-100) 
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